Skip to main content
. 2022 Apr 30;10(5):1038. doi: 10.3390/biomedicines10051038

Figure 4.

Figure 4

Therapeutic effect of the combination therapy of GILT and CXCR2-I on MV4-11 and primary AML-FLT3 BMMNC in vitro and ex vivo. (A) Representative FC plots of viable CD44+ MV4-11 cells (indicated by the red circle in the plot of No-Tx control) in different treatment groups including different doses of CXCR2-I alone or in combination with 80 nM GILT; Right bar chart: Cumulative FC percentage data of viable CD44+ blasts; Red curve arrows indicate the trend of dose-dependent treatment efficacy; (B) Representative FC plots of viable CD33+CD13+ primary blasts (Patient #3) in different treatment groups; Blue arrows (Gating) indicate further analyses of Ki-67 expression of these viable CD33+CD13+ primary blasts; (C) Cumulative FC percentage data of viable CD33+CD13+ primary blasts; (D) Cumulative FC percentage data of viable Ki-67+CD33+CD13+ primary blasts; * p < 0.05, ** p < 0.01, *** p < 0.005.